ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin
ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that further data from the first successful Phase III trial with microplasmin (TG-MV-006) for the non-surgical treatment of vitreomacular adhesion (VMA) were presented at the World Ophthalmology Congress by Dr. Matthew Benz, MD (The …
Read more on SYS-CON Media
Related posts:
- Seeing the world with new eyes: Biosynthetic corneas restore vision in humans
- Smith Eye Specula New Ophthalmology Surgical Instrument
- Bowman Eye Specula New Ophthalmology Surgical Instrument
- World?s First Saliva Gland and Laser Artificial Cornea Implantation a Success
- Implantable Collamer Lens or ICL Eye Procedure Now Offered by Associates in Ophthalmology